Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I versus low-dose antithyroid drugs in Graves' hyperthyroidism after prior radioiodine
ChiCTR2200063809Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, randomised trial of iodine-131, methimazole and propylthiouracil in Graves' disease (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Effective rate (normal or reduced thyroid function) at 24 months. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
iodine-131methimazolepropylthiouracil
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ChiCTR2200063809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063809.